ReviewOncotarget2017
Review: Oncolytic virotherapy, updates and future directions.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 140 citations in OpenAlex.
- Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma.International journal of cancer · 2026Article
- The Role of Viral Dynamics and Infectivity in Models of Oncolytic Virotherapy for Tumours with Different Motility.Bulletin of mathematical biology · 2026Article
- Enhancing antitumor immunity through oncolytic viruses: advances in genetic engineering.Discover oncology · 2026Review
- Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation.Cells · 2026Review
- The Impact of Microbiome on Breast Cancer and Regulatory Strategies.Microorganisms · 2025Review
- Promising immunotherapeutic treatments for colon cancer.Medical oncology (Northwood, London, England) · 2025Review
- Article
- Gene and cell therapy of human genetic diseases: Recent advances and future directions.Journal of cellular and molecular medicine · 2024Review
- Cytocidal Effect of Irradiation on Gastric Cancer Cells Infected with a Recombinant Mammalian Orthoreovirus Expressing a Membrane-Targeted KillerRed.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC).British journal of cancer · 2023Article
- Agent-Based and Continuum Models for Spatial Dynamics of Infection by Oncolytic Viruses.Bulletin of mathematical biology · 2023Article
- Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4Molecular therapy oncolytics · 2022Article
- NAD+ depletion enhances reovirus-induced oncolysis in multiple myeloma.Molecular therapy oncolytics · 2022Article
- Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity.Journal for immunotherapy of cancer · 2022Article
- Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer.Frontiers in oncology · 2022Article
- Newcastle disease virus expressing an angiogenic inhibitor exerts an enhanced therapeutic efficacy in colon cancer model.PloS one · 2022Article
- Article
- Metabolic barriers to cancer immunotherapy.Nature reviews. Immunology · 2021Review
- Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry.Nature communications · 2021Article
- Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Oncolytic viruses (OVs) are viral strains that can infect and kill malignant cells while spare their normal counterparts. OVs can access cells through binding to receptors on their surface or through fusion with the plasma membrane and establish a lytic cycle in tumors, while leaving normal tissue essentially unharmed. Multiple viruses have been investigated in humans for the past century. IMLYGIC™ (T-VEC/Talimogene Laherparepvec), a genetically engineered Herpes Simplex Virus, is the first OV approved for use in the United States and the European Union for patients with locally advanced or non-resectable melanoma. Although OVs have a favorable toxicity profile and are impressively active anticancer agents
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.